Interesting, page-41

As per July 2018 Overview report - Viriathus

Imagion’s goals over the next 12 months are to:

Manufacture MagSense nanoparticles in sufficient quantities for clinical trials and develop a commercial version of the MagSense instrument;

Complete safety and toxicology studies and advance the MagSense HER2 breast cancer product into human feasibilities studies and pivotal human clinical trials;

Negotiate a licensing agreement with an industry partner covering applications for MagSense technology in solid tumor cancers.

- announcement soon DYOR